echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Simcere introduces 2 Alzheimer's disease drug candidates

    Simcere introduces 2 Alzheimer's disease drug candidates

    • Last Update: 2021-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 29, Simcere Pharmaceuticals and Vivoryon Therapeutics jointly announced that the two parties have established a strategic regional licensing cooperation to develop and commercialize Alzheimer’s targeting neurotoxic amyloid N3pE (pGlu-Aβ) in Greater China.


    According to the agreement, Simcere Pharmaceuticals will be permitted to develop and commercialize two AD drugs developed by Vivoryon in the Greater China region.


    Among them, varoglutamstat is an oral small molecule inhibitor of glutamyl peptide cyclase (QPCT)


    PBD-C06 is a humanized, deimmunized IgG1 antibody drug in the pre-clinical development stage.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.